Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer.

Genomic features controlling ESR1 binding and activity differ between endometrial and breast cancer, with SOX17 uniquely regulating ESR1 in endometrial cancer.

• Why it matters: Understanding these differences is crucial because ESR1 is a key oncogenic factor, yet therapies targeting it are less effective in endometrial cancer compared to breast cancer, highlighting a gap in targeted treatment strategies.
• What they did: Researchers used machine learning on genomic data from Ishikawa (endometrial) and T-47D (breast) cells, focusing on estrogen response elements and transcription factor binding, including CRISPR knockout experiments.
• The result: Findings reveal cell type-specific transcription factors like SOX17 in endometrial cancer, providing insights that could lead to more effective, tailored therapies targeting ESR1 in endometrial cancer.